A First-In-Human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647020 In Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Cofetuzumab pelidotin (Primary)
- Indications Breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 13 Aug 2017 Planned End Date changed from 1 Jul 2019 to 24 Jul 2019.
- 13 Aug 2017 Planned primary completion date changed from 1 Jul 2019 to 24 Jul 2019.
- 13 Aug 2017 Status changed from active, no longer recruiting to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History